Professor of Urology, University Miami School of Medicine
Urology
Dr. Mark S. Soloway, MD
|
|
Give Review
Mark Soloway practices Urology. He studied medicine at Case Western Reserve University School of Medicine. He received 9 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "Top Doctors:South Florida", "CMS Meaningful Use Stage 1 Certification", "SouthFloridaCEO: Top Doctors", "Miami Metro City Guide: Top Doctors", "Top Doctors: Florida", "Super Doctor" and "Top MD". Mark Soloway is also published. He has 96 publications published. The lastest publication: "Expectant Management of Low-Risk Bladder Cancer.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Expectant Management of Low-Risk Bladder Cancer.
- Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on Bladder cancer.
- Defining and Treating the Spectrum of Intermediate-Risk NMIBC.
- Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition.
- Re: overdiagnosis and overtreatment in Cancer: an opportunity for improvement.
- Differential Expression Of Stroma Derived Factor-1 Isoforms In Bladder Cancer.
- Giant neoBladder stone.
- Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate Cancer.
- Prognostic implications of partial sampling of radical Prostatectomy specimens: comparison of 3 methods.
- Comparative validation of nomograms predicting clinically insignificant prostate Cancer.
- Improving risk stratification in patients with prostate Cancer managed by active surveillance: a nomogram predicting the risk of biopsy progression.
- Biopsy features associated with prostate Cancer progression in active surveillance patients: comparison of three statistical models.
- Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate Cancer progression in active surveillance patients.
- Association of stress management skills and perceived stress with physical and emotional well-being among advanced prostrate Cancer survivors following androgen depriv...
- Partial sampling of radical Prostatectomy specimens: detection of positive margins and extraprostatic extension.
- A contemporary update on pathology standards for Bladder cancer: transurethral resection and radical cystectomy specimens.
- Re: Upper urinary tract recurrence following radical cystectomy for Bladder cancer: a meta-analysis on 13,185 patients.
- ICUD-EAU International Consultation on Bladder Cancer 2012: pathology.
- A multi-institutional evaluation of active surveillance for low risk prostate Cancer.
- Diffuse large B cell lymphoma of the spermatic cord: a case report and literature review.
- Bladder cancer: Lack of progress in Bladder cancer-what are the obstacles?
- Prostate Cancers of different zonal origin: clinicopathological characteristics and biochemical outcome after radical prostatectomy.
- Neoadjuvant and adjuvant chemotherapy for muscle-invasive Bladder cancer: The likelihood of initiation and completion.
- Long-term decrease in Bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy.
- Surgical margin status does not affect overall survival following radical Prostatectomy: a single institution experience with expectant management.
- Active surveillance for low-risk prostate Cancer: knowledge, acceptance and practice among urologists.
- Millon Behavioral Medicine Diagnostic (MBMD) Predicts Health-Related Quality of Life (HrQoL) over time among men treated for localized prostate Cancer.
- Clinical and demographic characteristics associated with prostate Cancer progression in patients on active surveillance.
- Pathological findings at radical Prostatectomy in patients initially managed by active surveillance: A comparative analysis.
- Chemokine and Chemokine Receptor Expression in Kidney Tumors: Molecular Profiling of Histological Subtypes and Association With Metastasis.
- Prostate sampling by 12-core biopsy: comparison of the biopsy results with tumor location in Prostatectomy specimens.
- How Can We Improve Outcomes for Upper Tract Urothelial Carcinoma?
- Tumor focality is not associated with biochemical outcome after radical Prostatectomy.
- Oncologic outcomes following radical Prostatectomy with intraoperative cell salvage.
- Clinically significant Gleason sum upgrade: external validation and head-to-head comparison of the existing nomograms.
- Pathologic evaluation of non-neoplastic Renal parenchyma in partial nephrectomy specimens.
- Dramatic Reduction in Tumor Burden with Neoadjuvant Sunitinib Prior to Bilateral Nephron-sparing Surgery.
- Active surveillance vs. treatment for low-risk prostate Cancer: a cost comparison.
- Factors that influence patient enrollment in active surveillance for low-risk prostate Cancer.
- Re: Williams et al.: Radical retropubic Prostatectomy and robotic-assisted laparoscopic Prostatectomy: likelihood of positive surgical margin(s) (Urology 2010;76:1097-...
- Radical Cystectomy for BCG failure: has the timing improved in recent years?
- Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive Bladder cancer.
- Editorial comment. Focal positive surgical margins decrease disease-free survival after radical Prostatectomy even in organ-confined disease.
- Point. Routine use of postoperative intravesical chemotherapy after TURBT-should it be done?
- Are patients with Hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey.
- Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant Prostate disease.
- "Complete transurethral resection of Bladder tumor": are the guidelines being followed?
- Techniques for avoidance of sternotomy and cardiopulmonary bypass during resection of extensive Renal cell carcinoma with vena caval tumor thrombus extension above the...
- Vascular stapling of the inferior vena cava: further refinement of techniques for the excision of extensive Renal cell carcinoma with unresectable vena-caval involvement.
- Hyaluronic acid and HYAL-1 in Prostate biopsy specimens: predictors of biochemical recurrence.
- The risk and prophylactic management of Bladder cancer after various forms of radiotherapy.
- Editorial comment. With many other neoplasms, Bladder cancer is heterogeneous.
- Radiation therapy for prostate cancer increases subsequent risk of Bladder and rectal cancer: a population based cohort study.
- Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter.
- Osteopontin and interleukin-8 expression is independently associated with prostate Cancer recurrence.
- Trends in Gleason score: concordance between biopsy and Prostatectomy over 15 years.
- Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy.
- Upper urinary tract Cancer--challenges for the urologist.
- Re: can restaging transurethral resection of T1 Bladder cancer select patients for immediate cystectomy? H. W. Herr, S. M. Donat and G. Dalbagni J Urol 2007; 177: 75-79.
- Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the Bladder.
- Intraoperative cell salvage during radical Cystectomy does not affect long-term survival.
- HAS1 expression in Bladder cancer and its relation to urinary HA test.
- We are not yet ready to abandon Cystoscopy.
- Does body mass index affect outcome after reconstruction of orthotopic neoBladder?
- Lack of progress in early diagnosis of Bladder cancer.
- Chemotherapy for Bladder cancer: treatment guidelines for neoadjuvant chemotherapy, Bladder preservation, adjuvant chemotherapy, and metastatic cancer.
- Muscle-invasive urothelial carcinoma of the Bladder.
- HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of Bladder cancer.
- Metastatic adenoid cystic carcinoma to the Kidney in a young woman.
- Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate Cancer recurrence.
- Complications of intravesical therapy for urothelial cancer of the Bladder.
- Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial Bladder preservation.
- The use of urine-based biomarkers in Bladder cancer.
- The diagnosis and staging of Bladder cancer: from RBCs to TURs.
- Eliminate the term "superficial" Bladder cancer.
- Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary Bladder.
- Prostate specific antigen recurrence rates are low after radical retropubic Prostatectomy and positive margins.
- Transurethral Bladder tumor resection: intraoperative and postoperative complications in a residency setting.
- Renal cell Cancer with invasive atrial tumor thrombus excised off-pump.
- Bladder carcinoma: where are the patient advocates?
- Renal cell carcinoma with tumor thrombus extending above diaphragm: avoiding cardiopulmonary bypass.
- Cystoprostatectomy and orthotopic ileal neoBladder reconstruction for management of bacille Calmette Guérin-induced Bladder contractures.
- Optimal management of the T1G3 Bladder cancer.
- Intraoperative cell salvage during radical Prostatectomy is not associated with greater biochemical recurrence rate.
- Evaluation of analgesic requirements and postoperative recovery after radical retropubic Prostatectomy using long-acting spinal anesthesia.
- Urethral recurrence after cystoProstatectomy: implications for urinary diversion and monitoring.
- Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate Cancer.
- Modified Pfannenstiel approach for radical retropubic Prostatectomy.
- Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate Cancer.
- Radical retropubic Prostatectomy in Hispanic patients.
- Do unto others--why I would want anesthesia for my Prostate biopsy.
- Editorial: Bladder cancer. How can we make a difference?
- Visual estimate of percent of carcinoma predicts recurrence after radical Prostatectomy.
- Expectant management of small, recurrent, noninvasive papillary Bladder tumors.
- A pelvic drain may be avoided after radical retropubic Prostatectomy.
Schools
Case Western Reserve University School of Medicine
Procedures Preformed
- AdRenalectomy
- Cystectomy
- Cystometry
- Cystotomy
- View All
Conditions Treated
- Bladder Atony
- Bladder Cancer
- Bladder Infection
- Bladder Stones
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Top Doctors:South Florida
- CMS Meaningful Use Stage 1 Certification
- SouthFloridaCEO: Top Doctors
- Miami Metro City Guide: Top Doctors
- Top Doctors: Florida
- Super Doctor
- Top MD
Education
-
Case Western Reserve University - University Hospitals -
Case Western Reserve University School of Medicine -
Northwestern University
Hospital
-
University of Miami Hospital -
Miami Veterans Affairs Healthcare System
Drug Facts
| NPI NUMBER | 1982633558 | |
| NPPES Provider LastName | SOLOWAY | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 331801430 | |
| NPPES Provider State | FL | |
| Specialty Description | Urology | |
| Total Claim Count | 1135.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 1.32 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1982633558 |
| Last Name Of The Provider | SOLOWAY |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. Alan S. Dansky, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Raymond J. Leveillee, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Bruce R. Kava, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Darren Bruck, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cosme A. Gomez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles M. Lynne, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter A. Mennie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristin A. Kozakowski, MD |
|
|
Dr. Eduardo Guzman Jr., MD |
|
|
Dr. Manuel O. Cruz-Diaz, MD |
|
|
Dr. Barbara A. Montford, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eran Rosenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert Marcovich, MD
This Doctor is OpenDoctor Recommended.
|